Medical Oncology, Год журнала: 2023, Номер 40(9)
Опубликована: Июль 29, 2023
Язык: Английский
Medical Oncology, Год журнала: 2023, Номер 40(9)
Опубликована: Июль 29, 2023
Язык: Английский
Bioengineering, Год журнала: 2023, Номер 10(7), С. 760 - 760
Опубликована: Июнь 25, 2023
Nano-oncology is a branch of biomedical research and engineering that focuses on using nanotechnology in cancer diagnosis treatment. Nanomaterials are extensively employed the field oncology because their minute size ultra-specificity. A wide range nanocarriers, such as dendrimers, micelles, PEGylated liposomes, polymeric nanoparticles used to facilitate efficient transport anti-cancer drugs at target tumor site. Real-time labeling monitoring cells quantum dots essential for determining level therapy needed The drug targeted site either by passive or active means. Passive targeting makes use microenvironment enhanced permeability retention effect, while involves ligand-coated nanoparticles. Nanotechnology being diagnose early stage detecting cancer-specific biomarkers imaging. implication employs photoinduced nanosensitizers, reverse multidrug resistance, enabling delivery CRISPR/Cas9 RNA molecules therapeutic applications. However, despite recent advancements nano-oncology, there need delve deeper into domain designing applying improved diagnostics.
Язык: Английский
Процитировано
73Cell Communication and Signaling, Год журнала: 2024, Номер 22(1)
Опубликована: Апрель 15, 2024
Abstract Cancer is a major public health problem worldwide with more than an estimated 19.3 million new cases in 2020. The occurrence rises dramatically age, and the overall risk accumulation combined tendency for cellular repair mechanisms to be less effective older individuals. Conventional cancer treatments, such as radiotherapy, surgery, chemotherapy, have been used decades combat cancer. However, emergence of novel fields research has led exploration innovative treatment approaches focused on immunotherapy, epigenetic therapy, targeted multi-omics, also multi-target therapy. hypothesis was based that drugs designed act against individual targets cannot usually battle multigenic diseases like Multi-target therapies, either combination or sequential order, recommended acquired intrinsic resistance anti-cancer treatments. Several studies multi-targeting treatments due their advantages include; overcoming clonal heterogeneity, lower multi-drug (MDR), decreased drug toxicity, thereby side effects. In this study, we'll discuss about drugs, benefits improving recent advances field multi-targeted drugs. Also, we will study performed clinical trials using therapeutic agents treatment.
Язык: Английский
Процитировано
42Theranostics, Год журнала: 2024, Номер 15(3), С. 993 - 1016
Опубликована: Дек. 2, 2024
Immunotherapy has transformed current cancer management, and it achieved significant progress over last decades. However, an immunosuppressive tumor microenvironment (TME) diminishes the effectiveness of immunotherapy by suppressing activity immune cells facilitating immune-evasion. Adenosine monophosphate-activated protein kinase (AMPK), a key modulator cellular energy metabolism homeostasis, gained growing attention in anti-tumor immunity. Metformin is usually considered as cornerstone diabetes its role activating AMPK pathway also been extensively explored therapy although findings on remain inconsistent. nanomedicine formulation found to hold potential reprogramming TME through immunometabolic modulation both cells. This review elaborates foundation via metformin-based nanomedicines, offering valuable insights for next generation therapy.
Язык: Английский
Процитировано
38Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Янв. 2, 2025
Cancers still globally endanger millions of people yearly; the incidences/mortalities colorectal cancers are particularly increasing. The natural nanoparticles (NPs) and marine biopolymers were anticipated to provide effectual safe significances for managing cancers. transformation curcumin nano-curcumin (NCur) was conducted with gum Arabic. resulted NCur utilized biosynthesis selenium NPs (SeNPs), then bioactive nanocomposites (NC) from them fucoidan (Fu) fabricated evaluated as candidates suppress (CaCo-2 HT-29) cells. NCur-synthesized SeNPs effectually produced mean diameters 34.67 ± 4.32 5.17 1.06 nm, respectively. plain NCs Fu/NCur/SeNPs characterization, infrared spectroscopy electron microscopy, emphasized their interaction conjugations. entire agents/NCs had potent cytotoxic effects against cancers' lines; NC most IC50 10.35 0.83 19.44 1.39 mg/L CaCo-2 HT-29 cells, respectively, which significantly exceeded action standard cisplatin drug. led vigorous DNA damages in cancerous proved comet assay. ultrastructure imagining (scanning/transmission microscopy) treated cells confirmed capability induce severe apoptosis deformation signs bio-based constituents advocate prospective applications preventing/managing adenocarcinoma.
Язык: Английский
Процитировано
6Advanced Materials, Год журнала: 2025, Номер unknown
Опубликована: Янв. 10, 2025
Abstract Cancer immunotherapy, which leverages immune system components to treat malignancies, has emerged as a cornerstone of contemporary therapeutic strategies. Yet, critical concerns about the efficacy and safety cancer immunotherapies remain formidable. Nanotechnology, especially polymeric nanoparticles (PNPs), offers unparalleled flexibility in manipulation‐from chemical composition physical properties precision control nanoassemblies. PNPs provide an optimal platform amplify potency minimize systematic toxicity broad spectrum immunotherapeutic modalities. In this comprehensive review, basics polymer chemistry, state‐of‐the‐art designs from physicochemical standpoint for encompassing vaccines, situ vaccination, adoptive T‐cell therapies, tumor‐infiltrating cell‐targeted antibodies, cytokine therapies are delineated. Each immunotherapy necessitates distinctively tailored design strategies nanoplatforms. The extensive applications PNPs, investigation their mechanisms action enhanced particularly focused on. profiles clinical research progress discussed. Additionally, forthcoming developments emergent trends nano‐immunotherapeutics poised transform treatment paradigms into clinics explored.
Язык: Английский
Процитировано
6Cancer Cell International, Год журнала: 2025, Номер 25(1)
Опубликована: Фев. 18, 2025
Abstract Researchers have found that mutations in the BRCA gene associated with breast cancer a 40–50% chance of being high risk for hereditary (BC). Therefore, detecting BRCA1 is crucial genetic analysis, early detection, and clinical treatment BC. Traditional detection methods include high-performance liquid chromatography (HPLC), single-strand conformation polymorphism assays (SSCP), PCR, real-time DNA sequencing. However, these are limited by cost, analysis time, complexity. it necessary to develop an ultrasensitive, fast, low-cost, simple method detection. In recent years, various BC biosensing strategies been investigated, including optical, electrical, electrochemical, mechanical biosensing. particular, sensitivity short times electrochemical biosensors make them suitable recognizing biomarkers. Additionally, can be increased incorporating nanomaterials. this regard, main focus present study introduction common diagnosing BRCA-1/2 genes. addition introducing as efficient tool, also discusses latest most significant developed gene.
Язык: Английский
Процитировано
3Medical Oncology, Год журнала: 2023, Номер 40(6)
Опубликована: Май 8, 2023
Язык: Английский
Процитировано
32International Journal of Pharmaceutics, Год журнала: 2023, Номер 640, С. 123017 - 123017
Опубликована: Май 5, 2023
Язык: Английский
Процитировано
25BMC Cancer, Год журнала: 2024, Номер 24(1)
Опубликована: Янв. 4, 2024
Abstract Background Zinc oxide nanoparticles (ZnONPs) have impressively shown their efficacy in targeting and therapy of cancer. The present research was designated to investigate the potential ZnONP nanocomposites as a cancer chemotherapeutic-based drug delivery system assess anti-tumor anti-inflammatory effectiveness combination with systemic chemotherapeutic drugs doxorubicin (DOX) folic acid (FA) Ehrlich ascites carcinoma (EAC) tumor cell line both vitro vivo. Methods Anti-tumor nanocomposites: ZnONPs, ZnONPs/FA, ZnONPs/DOX ZnONPs/DOX/FA against EAC evaluated by MTT assay. were analyzed vivo examination proliferation rate apoptosis cells flow cytometry, splenocytes count, level inflammatory markers interleukin 6 (IL-6) necrosis factor alpha (TNF-α), well liver kidney function EAC-challenged mice. Results In results showed that high anti-proliferative potency cells. Furthermore, study revealed treatment mice ZnONPs/DOX, ZnONPs/FA hindered implanted through lowering number increasing rate. Moreover, markedly decreased IL-6 TNF-α remarkably ameliorated damages elevated implantation cells, restoring functions be close naïve control. Conclusion may useful system. regimen approaches great increase effect conventional chemotherapy, overcoming resistance chemotherapeutics reducing side effects, offering promising for therapy.
Язык: Английский
Процитировано
14Cancer Nanotechnology, Год журнала: 2025, Номер 16(1)
Опубликована: Янв. 30, 2025
Язык: Английский
Процитировано
2